• Paul Alexander Kyrle, Konrad Binder, Sabine Eichinger, Reinhold Függer, Bernd Gollackner, J Michael Hiesmayr, Kurt Huber, Wielfried Lang, Peter Perger, Peter Quehenberger, Franz X Roithinger, Sabine Schmaldienst, Ansgar Weltermann, and Hans Domanovits.
• Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria, paul.kyrle@meduniwien.ac.at.
• Wien. Klin. Wochenschr. 2014 Sep 1; 126 (17-18): 503-8.

AbstractDabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has a favourable benefit-risk profile, it is being increasingly used. Dabigatran differs from vitamin K antagonists as regards its pharmacological characteristics and its impact on certain laboratory tests, and also in the lack of a direct antagonist that can reverse dabigatran-induced anticoagulation. In emergency settings such as acute bleeding, emergency surgery, acute coronary syndrome, thrombolysis for ischaemic stroke or overdosing, specific strategies are required. A working group of experts from various disciplines has developed strategies for the management of dabigatran-treated patients in emergency settings.

24 keywords...

hide…